Peptide Initiative

Peptides · Peptide comparison

Intermedin (Adrenomedullin-2) vs Thymosin Beta-4

A powerful peptide hormone that protects your heart and blood vessels while managing stress and inflammation naturally.

The body's natural healing peptide that accelerates tissue repair and reduces inflammation

  • Healing & Recovery
  • Healing & Recovery

At a glance

Quick comparison

Dose rangeIntermedin (Adrenomedullin-2)As prescribed–As prescribed mgThymosin Beta-42–5 mg
FrequencyIntermedin (Adrenomedullin-2)Once dailyThymosin Beta-4Twice weekly
AdministrationIntermedin (Adrenomedullin-2)As directed by healthcare providerThymosin Beta-4Subcutaneous injection
Cycle lengthIntermedin (Adrenomedullin-2)Ongoing/indefiniteThymosin Beta-48-12 weeks
Onset speedIntermedin (Adrenomedullin-2)Moderate (1-2 weeks)Thymosin Beta-4Moderate (1-2 weeks)
Evidence levelIntermedin (Adrenomedullin-2)Limited human trialsThymosin Beta-4Moderate human trials (Phase 1-2)

Efficacy

Benefit ratings

Cardiovascular Health & Protection

Intermedin (Adrenomedullin-2)72%
Thymosin Beta-4No recorded rating

Stress & Anxiety Management

Intermedin (Adrenomedullin-2)68%
Thymosin Beta-4No recorded rating

Anti-Inflammatory & Antioxidant Support

Intermedin (Adrenomedullin-2)64%
Thymosin Beta-4No recorded rating

Wound Healing

Intermedin (Adrenomedullin-2)No recorded rating
Thymosin Beta-495%

Inflammation Reduction

Intermedin (Adrenomedullin-2)No recorded rating
Thymosin Beta-488%

Tissue Regeneration

Intermedin (Adrenomedullin-2)No recorded rating
Thymosin Beta-492%

Technical data

Compound specifications

Intermedin (Adrenomedullin-2)

Molecular formula
C15H25NO5 (precursor compound)
Molecular weight
299.36 g/mol (precursor)
Half-life
Approximately 2-6 hours (varies by route of administration)
Bioavailability
Varies by route of administration
CAS number
148498-78-6

Thymosin Beta-4

Molecular formula
C212H350N56O78S
Molecular weight
4963
Half-life
Dose-dependent (increases with higher doses)
Bioavailability
100% (subcutaneous and intravenous)
CAS number
77591-33-4

Protocols

Dosing compared

Intermedin (Adrenomedullin-2)

No dose levels recorded.

Thymosin Beta-4

Subcutaneous injection

  • 2-5 mg (community injectable practice for 'TB-500')Once or twice weekly · 4-6 week loading phase, then weekly maintenanceDocumented community/research-practice injectable dosing for tissue repair; thymosin beta-4 has ~100% bioavailability by the subcutaneous route [1]. Not an FDA-approved use.

Topical ophthalmic (eye drops)

  • 0.1% (1 mg/mL) RGN-259 solution, 1 dropSeveral times daily (e.g. up to 5x/day) · 4 weeks0.1% RGN-259 ophthalmic solution used in phase III neurotrophic keratopathy and dry-eye trials, applied as eye drops several times daily for ~4 weeks [5].

Intravenous injection

  • 450-1200 mgIV push daily for the first 3 days, then weekly · Total of 7 doses over ~5 weeksDoses studied in the RGN-352 acute myocardial infarction clinical program, given IV after PCI [6].

Applications

Best suited for

Intermedin (Adrenomedullin-2)

Supporting cardiovascular health and heart function
Intermedin (Adrenomedullin-2) is particularly well-suited for individuals focused on supporting cardiovascular health and heart function. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Managing inflammation and oxidative stress
Intermedin (Adrenomedullin-2) is particularly well-suited for individuals focused on managing inflammation and oxidative stress. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Improving overall vascular health and circulation
Intermedin (Adrenomedullin-2) is particularly well-suited for individuals focused on improving overall vascular health and circulation. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Thymosin Beta-4

Post-Surgery Recovery
Accelerates healing of surgical wounds and reduces post-operative inflammation and scarring
Chronic Wound Management
Helps pressure ulcers, venous stasis ulcers, and other slow-healing wounds progress faster
Tissue Regeneration
Supports repair of damaged tissues from injury, burns, or degenerative conditions

Safety profile

Side effects

Intermedin (Adrenomedullin-2)

Common

  • Mild discomfort at treatment site
  • Flushing and mild facial redness
  • Dizziness or lightheadedness
  • Mild headache
  • Injection site reactions (redness, itching, swelling)
  • Nausea or mild gastrointestinal discomfort
  • Fatigue or mild energy changes
  • Transient hypotension (temporary low blood pressure)
  • Mild palpitations (in some individuals)

Serious

  • Severe allergic reaction

Thymosin Beta-4

Common

  • Injection site redness
  • Injection site swelling

Uncommon

  • Temporary mild headache
  • Mild bruising at injection site
  • Transient fatigue

Serious

  • Allergic reaction

Research status

Safety & evidence

Intermedin (Adrenomedullin-2)

Evidence level
Limited human trials
FDA status
Not FDA approved
Safety overview
Intermedin (Adrenomedullin-2) is an endogenous peptide hormone with systemic vascular and renal effects that warrant cautious use. As a vasodilator acting through CGRP and other peptide receptors, it can significantly lower blood pressure—a key safety consideration for hypotensive or cardiovascular-compromised individuals. Preclinical studies show dose-dependent hypotensive effects and tachycardia, limiting clinical translation. The compound remains largely experimental with limited safety data in humans outside specific research contexts.

Contraindications

  • Pregnancy and breastfeeding - insufficient safety data
  • Active cardiovascular events (heart attack, stroke)
  • Severe renal (kidney) impairment
  • Hypersensitivity to calcitonin family peptides
  • Uncontrolled endocrine disorders

Thymosin Beta-4

Evidence level
Moderate human trials (Phase 1-2)
FDA status
Research compound
Safety overview
Thymosin Beta-4 is a naturally occurring peptide found in all cells and body fluids in the human body. Clinical trials have demonstrated excellent safety even at very high doses. IV studies showed doses up to 1260 mg were well tolerated with no serious adverse events.

Contraindications

  • Active systemic infections
  • Severe immunosuppression
  • Hypersensitivity to thymosin or any component
  • Pregnancy (insufficient safety data)

Decision guide

Which is right for you?

Intermedin (Adrenomedullin-2)

Choose Intermedin (Adrenomedullin-2) if…

  • Supporting cardiovascular health and heart function
  • Managing inflammation and oxidative stress
  • Improving overall vascular health and circulation

Thymosin Beta-4

Choose Thymosin Beta-4 if…

  • Recovering from injuries or surgery
  • Improving wound healing speed
  • Reducing inflammation
  • Minimizing scar formation